A toxic chemical long considered hostile to life on Mars, may not be an obstacle to building on the Red Planet after all. Instead, it could.

Alien Isolation 2 made headlines when the sequel was first announced in October 2024. The announcement was part of the 10th anniversary celebration of the first Alien Isolation game, which was ...

In July, researchers using the NASA-funded Asteroid Terrestrial-impact Last Alert System survey telescope in Chile made an exceedingly rare discovery: a mysterious object passing through the solar ...

A Texas teenager was rescued by her father after she was forced into a truck at knifepoint on Christmas Day, police said. Patrol deputies with the Montgomery County Sheriff's Office were called to an ...

Kerry Breen is a news editor at CBSNews.com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital. She covers current events, ...

Hope Biosciences has linked its stem cell therapy candidate to improved motor function in Parkinson’s disease patients in a phase 2 trial. The single-site study randomized 60 people with early to ...

At its annual Ecosystem Day on December 12, Hithium Energy Storage signaled a strategic improvement beyond conventional four-hour batteries, positioning long-duration storage as both a grid asset and ...

The ongoing phase I/II clinical trial is evaluating the safety, tolerability and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001 Preliminary findings include a ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

BOSTON — Nov. 20, 2025 — Ginkgo Bioworks (NYSE: DNA) today announced the launch of the Virtual Cell Pharmacology Initiative (VCPI) through Ginkgo Datapoints. This open-source platform is designed to ...

Shares of Agios Pharmaceuticals (AGIO) plunged ~45% in the premarket on Wednesday after the biotech announced a mixed outcome from a late-stage trial for its lead asset mitapivat in sickle cell ...